Genomic profiling of Indian gallbladder carcinoma: mutational insights in a high-incidence population
The largest Indian series, 376 patients sequenced at three centres, found the disease strikes a decade earlier than elsewhere, with TP53 and HER2 the leading changes and immunotherapy markers rare.
Overview
376 patients with gallbladder carcinoma (339 tissue and 37 plasma cell-free DNA samples) from three Indian institutions (2022 to 2024) were analysed with clinically validated next-generation sequencing panels and compared with Western, Asian and multi-ethnic cohorts curated from cBioPortal. The disease was more frequent in women (1.5 to 1) and diagnosed nearly a decade earlier than in international cohorts (median age 54).
TP53 (54%) and ERBB2 (15%; approximately 8% amplification, with S310F/Y hotspot predominance) were the most common alterations, followed by CDKN2A (9%), KRAS (7%) and SMAD4 (7%). Microsatellite instability-high (0.6%, 2 of 170 tested) and tumour mutational burden-high (1.3%, 1 of 79 tested) were rare. Indian patients had significantly lower ARID1A, SMAD4 and CDKN2A alteration rates than Western and Asian cohorts (all P < 0.001). Of 37 cfDNA patients, 13 showed no variants, but detected alterations qualitatively mirrored tissue.
- TP53 54%, ERBB2 15% (about 8% amplification; S310F/Y hotspot), CDKN2A 9%, KRAS 7%, SMAD4 7%.
- MSI-high 0.6% (2 of 170) and TMB-high 1.3% (1 of 79).
- ARID1A, SMAD4 and CDKN2A significantly less altered than in Western and Asian cohorts; median age at diagnosis 54.
HER2 is as frequent in India as in the West, so HER2 testing pays off in the highest-incidence population, while tumour-agnostic immunotherapy markers will rarely apply. The paper also shows plasma testing is feasible where tissue is scarce.
- Heterogeneous panels across three institutions introduce variability in frequency estimates, as the authors state.
- Retrospective series of patients who reached sequencing.
Similar pages
not linked directly; found by shared links- Key paperComprehensive molecular characterization of gallbladder carcinoma and potential targets for intervention
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), SMAD4, MSI-high (microsatellite instability by PCR or sequencing), CDKN2A.
- Key paperBiliary cancer: utility of next-generation sequencing for clinical management
- Key paperPopulation-Specific Immunogenomic Alterations in Gallbladder Cancer and Prognostic Significance
- Key paperMolecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets
Shares Mismatch repair proteins (MLH1, MSH2, MSH6, PMS2), Tumour mutational burden (TMB), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), HER2.
- Key paperMismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma
Shares Mismatch repair proteins (MLH1, MSH2, MSH6, PMS2), MSI-high (microsatellite instability by PCR or sequencing), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Gallbladder cancer.
- Key paperIntegrative molecular characterisation of gallbladder cancer reveals micro-environment-associated subtypes
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), Tumour mutational burden (TMB), TP53, Gallbladder cancer.
- Key paperMolecular and clinical determinants of targeted therapy treatment in biliary tract cancer
- Key paperClinical and genomic characterization of ERBB2-altered gallbladder cancer: exploring differences between an American and a Chilean cohort
Shares HER2 (ERBB2) activating mutation, HER2 testing in biliary tract cancer (IHC, ISH and NGS), HER2, Gallbladder cancer.